# SS-31 vs MOTS-c · PepVault guides

Source: https://pepvault.app/guides/ss-31-vs-mots-c

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [The science](https://pepvault.app/guides#science)

# SS-31 vs MOTS-c: where each works and what the human data show

Reviewed November 2026 18 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

SS-31 vs MOTS-c side by side: where each acts in the mitochondrion, the human evidence for each in one table, and what is known about taking them together.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 18
- **Questions:** 8
- **Compounds:** 2

## The short answer

SS-31 and MOTS-c both target mitochondria, from opposite sides. SS-31 (elamipretide) is a lab-made, four-amino-acid drug that sits on cardiolipin in the inner membrane; the FDA approved it in 2025 for Barth syndrome, though its larger trials missed. MOTS-c is a 16-amino-acid signal the mitochondria make themselves, strong in mice but never given to people in a published trial.

Every number checked at its primary source · Nov 20, 2026 · [18 sources](https://pepvault.app/guides/ss-31-vs-mots-c#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Uneven: SS-31 has randomized human trials, mostly negative, and an FDA accelerated approval in Barth syndrome built on 12 patients; MOTS-c's effects as a treatment come from mouse and cell studies, with human data limited to the body's own levels, genetics and one analog trial.

## What is the difference between SS-31 and MOTS-c?

Mitochondria are the structures inside cells that turn food and oxygen into ATP, the cell's energy currency. Both are called mitochondrial peptides, a label that hides how different they are. SS-31 is a drug that chemists designed: four amino acids, one of them a modified tyrosine and one a mirror-image arginine, small enough to slip into the cell and settle on the inner mitochondrial membrane[1](https://pepvault.app/guides/ss-31-vs-mots-c#source-1) [2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2). MOTS-c is something your body already makes. Its recipe is written in the mitochondria's own small genome, inside the gene for a ribosomal RNA, and it is 16 amino acids long[4](https://pepvault.app/guides/ss-31-vs-mots-c#source-4) [17](https://pepvault.app/guides/ss-31-vs-mots-c#source-17).

Put simply, SS-31 is a repair crew on the factory floor, and MOTS-c is a message the factory sends out to the rest of the cell.

| At a glance | SS-31 (elamipretide) | MOTS-c |
| --- | --- | --- |
| Where it comes from | Designed in a lab; not made by the body | Made by the body, coded in mitochondrial DNA |
| Size | 4 amino acids, about 640 daltons (749 as the label's salt)[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2) | 16 amino acids, about 2,175 daltons[17](https://pepvault.app/guides/ss-31-vs-mots-c#source-17) |
| Where it acts | On the inner mitochondrial membrane[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2) | Outside the mitochondria: the cell's fluid and its nucleus[4](https://pepvault.app/guides/ss-31-vs-mots-c#source-4) [5](https://pepvault.app/guides/ss-31-vs-mots-c#source-5) |
| What it binds or switches on | Cardiolipin, a membrane fat[1](https://pepvault.app/guides/ss-31-vs-mots-c#source-1) | AMPK, the cell's fuel gauge[4](https://pepvault.app/guides/ss-31-vs-mots-c#source-4) |
| Status, November 2026 | FDA-approved for Barth syndrome (accelerated)[3](https://pepvault.app/guides/ss-31-vs-mots-c#source-3) | Not approved; the FDA lists compounding risks, and its compounding nomination was withdrawn[12](https://pepvault.app/guides/ss-31-vs-mots-c#source-12) |
| Published human trials of the molecule | Several, including a 218-person phase 3[7](https://pepvault.app/guides/ss-31-vs-mots-c#source-7) | None |

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

In PepVault both fit one protocol: SS-31 every day and MOTS-c on the days you pick, such as Monday, Wednesday and Friday. Each can have its own reminder time, and Today shows only what is due.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Where does each act in the mitochondrion?

A mitochondrion has two membranes. The inner one is folded into ridges called cristae, and that is where the chain of enzymes that makes ATP sits. A fat called **cardiolipin** is found only in that inner membrane: it holds the folds in shape, keeps the enzymes packed together so they work as a chain, and decides whether a protein called cytochrome c carries electrons, its normal job, or turns into an enzyme that damages fats[1](https://pepvault.app/guides/ss-31-vs-mots-c#source-1). SS-31 binds cardiolipin through electric charge and water-repelling contacts, keeps cytochrome c on its normal job and protects the cristae[1](https://pepvault.app/guides/ss-31-vs-mots-c#source-1). The FDA label puts it in one line: a cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial shape and function[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2).

MOTS-c does its work after it leaves. In the 2015 paper that named it, its main target was skeletal muscle: it slowed the folate cycle and the purine building tied to it, and that switched on **AMPK**, the enzyme that senses low energy and tells the cell to take up and burn more glucose and fat[4](https://pepvault.app/guides/ss-31-vs-mots-c#source-4). In 2018 the same lab showed that under metabolic stress, such as glucose running short, MOTS-c moves into the nucleus and changes which of the nucleus's genes are read, including antioxidant-defence genes run by a switch called NRF2[5](https://pepvault.app/guides/ss-31-vs-mots-c#source-5).

Both mechanisms come from cell and animal studies (pepvault.app/glossary/in-vitro and /glossary/in-vivo). Results in cells and mice often don't carry over to people, which is why the next table matters more.

## What is the human evidence for SS-31 and MOTS-c?

SS-31 has been given to hundreds of people in controlled trials. MOTS-c has been measured in people and studied through their genes, but every published study that gave it as a treatment used mice or cells. The one human drug trial in its family tested an analog, a modified molecule, CB4211.

| Study | Peptide | Who | What it found |
| --- | --- | --- | --- |
| TAZPOWER, on the label[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2) | SS-31 | 12 people with Barth syndrome, 40 mg a day | Missed both main goals over 12 randomized weeks; knee strength rose in the open-label years after, the basis of the 2025 approval |
| MMPOWER-3, 2023[7](https://pepvault.app/guides/ss-31-vs-mots-c#source-7) | SS-31 | 218 adults with mitochondrial myopathy, 40 mg a day for 24 weeks | No benefit: walk-test difference of -3.2 m against placebo (p = 0.69) |
| Roshanravan, 2021[8](https://pepvault.app/guides/ss-31-vs-mots-c#source-8) | SS-31 | 39 adults aged 60 to 85, one 2-hour infusion | Muscle energy capacity rose right after the dose, gone by day 7; no change in fatigue resistance |
| Reynolds, 2021[6](https://pepvault.app/guides/ss-31-vs-mots-c#source-6) | MOTS-c (the body's own) | 10 sedentary young men, one cycling session | Muscle MOTS-c up 11.9-fold; blood up 1.6-fold, back to baseline 4 hours later |
| Zempo, 2021[9](https://pepvault.app/guides/ss-31-vs-mots-c#source-9) | MOTS-c (a gene variant) | 27,527 people in three cohorts, two in Japan, one in the US | Men, not women, carrying the K14Q variant, which swaps one amino acid, had more type 2 diabetes |
| CB4211 phase 1b[10](https://pepvault.app/guides/ss-31-vs-mots-c#source-10) [11](https://pepvault.app/guides/ss-31-vs-mots-c#source-11) | A MOTS-c analog | 20 people with fatty liver, 25 mg or placebo daily for 4 weeks | ALT, a liver-damage marker, down 21% against up 4%; liver fat fell 5.03 points against 4.88 on placebo |

SS-31 is the only one of the two with randomized evidence in people, and most of it is negative or short: the approval rests on 12 patients and an open-label extension, meaning everyone knew they were on the drug[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2). MOTS-c's human record is a set of strong clues, since exercise raises it and a variant that weakens it tracks with diabetes, but none shows what an injection does. The FDA's compounding page, current as of April 22, 2026, says the agency has not identified any human exposure data on drug products containing MOTS-c given by any route[12](https://pepvault.app/guides/ss-31-vs-mots-c#source-12).

## With this guide

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### MOTS-c

- [MOTS-c: the full reference](https://pepvault.app/peptides/mots-c)
- [MOTS-c dose guide](https://pepvault.app/lab/dosage/mots-c)

### Mixing charts

- [SS-31 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [SS-31 50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)
- [MOTS-c 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/mots-c-10mg)
- [MOTS-c 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/mots-c-40mg)

### Studies

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial](https://pepvault.app/research/ss-31-mmpower-3-2023)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [All 14 studies](https://pepvault.app/research#ss-31)
- [MOTS-c rose after 16 weeks of exercise in non-Hispanic White survivors](https://pepvault.app/research/mots-c-dieli-conwright-2021)
- [MOTS-c reduced islet cell senescence and glucose intolerance in mice](https://pepvault.app/research/mots-c-kong-2025)
- [MOTS-c eased lung ischemia-reperfusion injury and deaths in rats](https://pepvault.app/research/mots-c-li-2025)
- [All 12 studies](https://pepvault.app/research#mots-c)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)
- [MOTS-c vs SLU-PP-332](https://pepvault.app/peptides/compare/mots-c-vs-slu-pp-332)
- [NAD+ vs MOTS-c](https://pepvault.app/peptides/compare/nad-vs-mots-c)
- [Epitalon vs MOTS-c](https://pepvault.app/peptides/compare/epitalon-vs-mots-c)
- [MOTS-c vs Humanin](https://pepvault.app/peptides/compare/mots-c-vs-humanin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Skin and longevity path

- [GHK-Cu for skin and hair: what's measured](https://pepvault.app/guides/ghk-cu-skin-and-hair)
- [Melanotan 1 vs 2: what each one does](https://pepvault.app/guides/melanotan-1-vs-melanotan-2)
- [What is Cerebrolysin? The trial evidence](https://pepvault.app/guides/cerebrolysin-explained)
- [Khavinson bioregulators, explained](https://pepvault.app/guides/khavinson-bioregulators-explained)
- [SS-31 (elamipretide): what the trials show](https://pepvault.app/guides/ss-31-elamipretide)
- [MOTS-c: the mouse and human studies](https://pepvault.app/guides/mots-c-studies)
- [Are collagen peptides the same as research peptides?](https://pepvault.app/guides/collagen-vs-research-peptides)
- [GHK-Cu vs minoxidil for hair: the evidence side by side](https://pepvault.app/guides/ghk-cu-vs-minoxidil-for-hair)
- [GHK-Cu injection vs topical: what the studies show](https://pepvault.app/guides/ghk-cu-injection-vs-topical)
- [Thymulin vs Thymalin: what's the difference?](https://pepvault.app/guides/thymulin-vs-thymalin)
- [Semax and Selank: what the studies found](https://pepvault.app/guides/semax-and-selank)
- [PT-141 (bremelanotide) for women and men: what the trials measured](https://pepvault.app/guides/pt-141-bremelanotide)
- [PT-141 nasal spray: does it work?](https://pepvault.app/guides/pt-141-nasal-spray)
- [How to reconstitute NAD+, and how often the studies gave it](https://pepvault.app/guides/nad-plus-mixing-and-how-often)
- [The FDA peptide panel explained: both meetings and what each vote means](https://pepvault.app/guides/fda-peptide-panel-explained)
- [Low-dose naltrexone (LDN): what it's used for and what the trials show](https://pepvault.app/guides/low-dose-naltrexone)
- [Is low-dose naltrexone (LDN) safe in pregnancy, and before trying to conceive?](https://pepvault.app/guides/ldn-and-pregnancy)
- [Do you stop low-dose naltrexone (LDN) before surgery or a colonoscopy?](https://pepvault.app/guides/ldn-before-surgery)
- [Does minoxidil cause hair loss?](https://pepvault.app/guides/minoxidil-shedding)
- [Can you take minoxidil with finasteride?](https://pepvault.app/guides/minoxidil-with-finasteride)
- [Peptides for hair growth: what the studies show](https://pepvault.app/guides/peptides-for-hair-growth)
- [Peptides for skin: what the human studies show](https://pepvault.app/guides/peptides-for-skin)
- [Do tanning peptides protect you from the sun?](https://pepvault.app/guides/tanning-peptides-and-the-sun)
- [Tretinoin vs retinol vs GHK-Cu for skin](https://pepvault.app/guides/tretinoin-vs-retinol-vs-ghk-cu)
- [Epitalon and telomeres: what was measured](https://pepvault.app/guides/epitalon-and-telomeres)
- [Dihexa: what is known, and what is not](https://pepvault.app/guides/dihexa-what-is-known)
- [Does Pinealon help sleep, and why does it make some people sleepy?](https://pepvault.app/guides/pinealon-and-sleep)
- [Selank vs oxytocin for anxiety: what the trials found](https://pepvault.app/guides/selank-vs-oxytocin-for-anxiety)
- [Oxytocin nasal spray: what it is used for](https://pepvault.app/guides/oxytocin-nasal-spray)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Cycle](https://pepvault.app/glossary/cycle)
- [Stack](https://pepvault.app/glossary/stack)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Accelerated approval](https://pepvault.app/glossary/accelerated-approval)
- [Open-label](https://pepvault.app/glossary/open-label)

## Which SS-31 trials are still to report?

As of November 2026, ClinicalTrials.gov lists the next readouts for SS-31, all from or with its developer, Stealth BioTherapeutics:

- **ReNEW:** 313 people with dry age-related macular degeneration, enrolment closed, main results due around August 2027[13](https://pepvault.app/guides/ss-31-vs-mots-c#source-13).
- **4TAZPower:** the confirmatory Barth syndrome trial that continued approval may depend on, 48 people, due around September 2029[14](https://pepvault.app/guides/ss-31-vs-mots-c#source-14).
- **SHAPE:** a University of Washington pilot in 30 healthy adults aged 65 to 80, a daily injection for 4 weeks, open-label and mainly a safety test; its listed end date, April 2026, has passed with no update[15](https://pepvault.app/guides/ss-31-vs-mots-c#source-15).
- **NuPower:** 102 people with mitochondrial disease from nuclear DNA mutations, completed in 2024, with no results posted[18](https://pepvault.app/guides/ss-31-vs-mots-c#source-18).

MOTS-c has no published trial to wait on, and CB4211's topline numbers, released in 2021 and restated in a 2022 annual filing, have had no paper since[10](https://pepvault.app/guides/ss-31-vs-mots-c#source-10).

## How are SS-31 and MOTS-c dosed, and how long do they last?

The SS-31 label dose for Barth syndrome is 40 mg injected under the skin once a day, the dose most of its long trials used[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2) [7](https://pepvault.app/guides/ss-31-vs-mots-c#source-7). It peaks in the blood 30 to 60 minutes after the injection, about 92% of it reaches the bloodstream, and by 48 hours about 100% of the dose has left in the urine[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2). The label gives no half-life figure, and the older-adult study's effect was gone a week after one dose[8](https://pepvault.app/guides/ss-31-vs-mots-c#source-8). MOTS-c has no published human pharmacokinetics at all. The half-lives some comparison pages print, 30 minutes for MOTS-c and 2 hours for SS-31, cite no source.

| Dosing | SS-31 | MOTS-c |
| --- | --- | --- |
| Label or trial schedule | 40 mg once a day, under the skin[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2) | None in people; mouse studies dosed by body weight[4](https://pepvault.app/guides/ss-31-vs-mots-c#source-4) [6](https://pepvault.app/guides/ss-31-vs-mots-c#source-6) |
| Community schedule | Usually 2 to 4 mg a day | Usually 5 to 10 mg, 2 or 3 times a week |
| Peak in blood | 30 to 60 minutes[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2) | Not measured in people |

The community amounts come from protocols, not studies. For SS-31 they sit far below the label's 40 mg, though the label notes that blood levels rise in step with the dose across 2 to 80 mg[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2). Both ranges, with that caveat, are at pepvault.app/lab/dosage/ss-31 and pepvault.app/lab/dosage/mots-c.

These are the amounts the label, the trials and community protocols describe, not a protocol to copy.

## Can you take SS-31 and MOTS-c together?

People do: it is a common longevity pairing, and the two make up the Longevity Core stack with epitalon (pepvault.app/stacks/mots-c-epitalon-ss-31). The rationale follows the mechanisms. SS-31 protects the membrane where energy is made; MOTS-c changes how the cell spends fuel. Because they act on different targets, neither is expected to block the other.

No study has tested that. A PubMed search for both names together (November 20, 2026) returns one record, a 2026 review of peptides in sports medicine that covers each one separately[16](https://pepvault.app/guides/ss-31-vs-mots-c#source-16). The advice some sellers give, to run SS-31 for weeks first and add MOTS-c later, is opinion. Because MOTS-c works on glucose handling in animals[4](https://pepvault.app/guides/ss-31-vs-mots-c#source-4), anyone on insulin or other diabetes medicine has good reason to talk glucose with their doctor first.

<!--promo-->

In PepVault both fit one protocol: SS-31 every day and MOTS-c on the days you pick, such as Monday, Wednesday and Friday. Each can have its own reminder time, and Today shows only what is due. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-ss-31-vs-mots-c-inline&mt=8)

<!--/promo-->

**Commonly reported:** on SS-31, steadier energy and less of a crash after exercise, building over weeks; on MOTS-c, a tired first week or two, then easier workouts by weeks two to four.

## What side effects do SS-31 and MOTS-c cause?

For SS-31 the label has real numbers. In the Barth trial, all 12 patients had redness at the injection site on elamipretide, against 3 of 12 on placebo, and 75% had pain there[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2). Eosinophils, a type of white blood cell, often rose in courses of a month or more, peaked around day 90 and settled after 6 to 12 months, with no symptoms attached[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2). In MMPOWER-3 most side effects were mild to moderate[7](https://pepvault.app/guides/ss-31-vs-mots-c#source-7).

For MOTS-c there is no human safety data. The nearest is the analog: CB4211's volunteers had mild, mostly painless bumps under the skin where they injected, which stopped lasting after a change of formulation[10](https://pepvault.app/guides/ss-31-vs-mots-c#source-10). The FDA's concern with compounded MOTS-c is immunogenicity, the chance the immune system reacts against the peptide (pepvault.app/glossary/immunogenicity)[12](https://pepvault.app/guides/ss-31-vs-mots-c#source-12).

<!--promo-->

Two injected peptides means more sites to rotate. Each shot you log in PepVault records where it went, so the last few sites are in front of you before the next one. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-ss-31-vs-mots-c-inline&mt=8)

<!--/promo-->

**When to get help** If a rash, a cough or other signs of an allergic reaction follow a dose, the SS-31 label's advice is to stop and get medical help right away[2](https://pepvault.app/guides/ss-31-vs-mots-c#source-2).

## Where to read more

- Each one in depth: the guides SS-31 (elamipretide), what the trials show, and MOTS-c, the mouse and human studies.
- The library pages, pepvault.app/peptides/ss-31 and pepvault.app/peptides/mots-c, with their legal status pages, and the short comparison at pepvault.app/peptides/compare/mots-c-vs-ss-31.
- The study pages, such as pepvault.app/research/ss-31-mmpower-3-2023, pepvault.app/research/ss-31-roshanravan-2021, pepvault.app/research/mots-c-lee-2015 and pepvault.app/research/mots-c-reynolds-2021.
- Open-label, primary endpoint and accelerated approval are explained at pepvault.app/glossary/open-label, /glossary/primary-endpoint and /glossary/accelerated-approval.
- Next guide: NAD+ vs NMN vs NR, what each is and what the human trials measured.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. [PubMed 24117165](https://pubmed.ncbi.nlm.nih.gov/24117165/)
2. FORZINITY (elamipretide) injection, prescribing information. Stealth BioTherapeutics. DailyMed, version 11, November 6, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75)
3. U.S. Food and Drug Administration. Drugs@FDA: NDA 215244, Forzinity (elamipretide), original approval September 19, 2025 (Type 1, new molecular entity). [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215244)
4. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. [PubMed 25738459](https://pubmed.ncbi.nlm.nih.gov/25738459/)
5. Kim KH et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018. [PubMed 29983246](https://pubmed.ncbi.nlm.nih.gov/29983246/)
6. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. [PubMed 33473109](https://pubmed.ncbi.nlm.nih.gov/33473109/)
7. Karaa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023. [PubMed 37268435](https://pubmed.ncbi.nlm.nih.gov/37268435/)
8. Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. [PubMed 34264994](https://pubmed.ncbi.nlm.nih.gov/34264994/)
9. Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021. [PubMed 33468709](https://pubmed.ncbi.nlm.nih.gov/33468709/)
10. CohBar, Inc. Annual report on Form 10-K for 2021, filed with the U.S. Securities and Exchange Commission, March 29, 2022. [sec.gov](https://www.sec.gov/Archives/edgar/data/1522602/000121390022015833/f10k2021_cohbarinc.htm)
11. ClinicalTrials.gov NCT03998514. A phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease. Sponsor: CohBar, Inc. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03998514)
12. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). [fda.gov](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)
13. ClinicalTrials.gov NCT06373731. ReNEW: phase 3 of subcutaneous elamipretide in dry age-related macular degeneration. Sponsor: Stealth BioTherapeutics Inc. Record updated September 17, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06373731)
14. ClinicalTrials.gov NCT07531251. 4TAZPower: confirmatory trial of elamipretide in Barth syndrome. Sponsor: Stealth BioTherapeutics Inc. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07531251)
15. ClinicalTrials.gov NCT07275424. SHAPE: open-label phase 2a pilot of daily subcutaneous elamipretide in older adults. Sponsor: University of Washington (D. Marcinek), with Stealth BioTherapeutics. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07275424)
16. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026. [PubMed 41966639](https://pubmed.ncbi.nlm.nih.gov/41966639/)
17. UniProt A0A0C5B5G6. Mitochondrial-derived peptide MOTS-c (human, gene MT-RNR1): sequence and mass. [rest.uniprot.org](https://rest.uniprot.org/uniprotkb/A0A0C5B5G6.json)
18. ClinicalTrials.gov NCT05162768. NuPower: elamipretide in primary mitochondrial disease from nuclear DNA mutations. Sponsor: Stealth BioTherapeutics Inc. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05162768)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · Skin and longevity

Guide · Skin and longevity

### [Are collagen peptides the same as research peptides?](https://pepvault.app/guides/collagen-vs-research-peptides)

Collagen peptides are food protein eaten by the gram; BPC-157 and GHK-Cu are exact chains used in milligrams. One table, then collagen's skin and joint trials.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [SS-31 Studied range: 2–4 mg](https://pepvault.app/peptides/ss-31)
- [MOTS-c Studied range: 5–10 mg](https://pepvault.app/peptides/mots-c)

## Related guides

- Guide · The science

  ### [SS-31 (elamipretide): what the trials show](https://pepvault.app/guides/ss-31-elamipretide)

  SS-31 (elamipretide) binds cardiolipin inside mitochondria: what it does, its 2025 FDA approval in Barth syndrome, and where the larger trials fell short.

  Read the guide
- Guide · The science

  ### [MOTS-c: the mouse and human studies](https://pepvault.app/guides/mots-c-studies)

  MOTS-c improved insulin sensitivity and running in mice. Human studies have only measured the body's own levels. What each study found, and what's missing.

  Read the guide
- Guide · Longevity and supplements

  ### [NAD+ vs NMN vs NR: what each is and what the human trials measured](https://pepvault.app/guides/nad-vs-nmn-vs-nr)

  NR and NMN both doubled blood NAD+ in the one head-to-head trial; injected NAD+ is the least measured. 13 human trials per form, with what each changed.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### MOTS-c

- [MOTS-c: the full reference](https://pepvault.app/peptides/mots-c)
- [MOTS-c dose guide](https://pepvault.app/lab/dosage/mots-c)

### Mixing charts

- [SS-31 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [SS-31 50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)
- [MOTS-c 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/mots-c-10mg)
- [MOTS-c 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/mots-c-40mg)

### Studies

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial](https://pepvault.app/research/ss-31-mmpower-3-2023)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [All 14 studies](https://pepvault.app/research#ss-31)
- [MOTS-c rose after 16 weeks of exercise in non-Hispanic White survivors](https://pepvault.app/research/mots-c-dieli-conwright-2021)
- [MOTS-c reduced islet cell senescence and glucose intolerance in mice](https://pepvault.app/research/mots-c-kong-2025)
- [MOTS-c eased lung ischemia-reperfusion injury and deaths in rats](https://pepvault.app/research/mots-c-li-2025)
- [All 12 studies](https://pepvault.app/research#mots-c)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)
- [MOTS-c vs SLU-PP-332](https://pepvault.app/peptides/compare/mots-c-vs-slu-pp-332)
- [NAD+ vs MOTS-c](https://pepvault.app/peptides/compare/nad-vs-mots-c)
- [Epitalon vs MOTS-c](https://pepvault.app/peptides/compare/epitalon-vs-mots-c)
- [MOTS-c vs Humanin](https://pepvault.app/peptides/compare/mots-c-vs-humanin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Skin and longevity path

- [GHK-Cu for skin and hair: what's measured](https://pepvault.app/guides/ghk-cu-skin-and-hair)
- [Melanotan 1 vs 2: what each one does](https://pepvault.app/guides/melanotan-1-vs-melanotan-2)
- [What is Cerebrolysin? The trial evidence](https://pepvault.app/guides/cerebrolysin-explained)
- [Khavinson bioregulators, explained](https://pepvault.app/guides/khavinson-bioregulators-explained)
- [SS-31 (elamipretide): what the trials show](https://pepvault.app/guides/ss-31-elamipretide)
- [MOTS-c: the mouse and human studies](https://pepvault.app/guides/mots-c-studies)
- [Are collagen peptides the same as research peptides?](https://pepvault.app/guides/collagen-vs-research-peptides)
- [GHK-Cu vs minoxidil for hair: the evidence side by side](https://pepvault.app/guides/ghk-cu-vs-minoxidil-for-hair)
- [GHK-Cu injection vs topical: what the studies show](https://pepvault.app/guides/ghk-cu-injection-vs-topical)
- [Thymulin vs Thymalin: what's the difference?](https://pepvault.app/guides/thymulin-vs-thymalin)
- [Semax and Selank: what the studies found](https://pepvault.app/guides/semax-and-selank)
- [PT-141 (bremelanotide) for women and men: what the trials measured](https://pepvault.app/guides/pt-141-bremelanotide)
- [PT-141 nasal spray: does it work?](https://pepvault.app/guides/pt-141-nasal-spray)
- [How to reconstitute NAD+, and how often the studies gave it](https://pepvault.app/guides/nad-plus-mixing-and-how-often)
- [The FDA peptide panel explained: both meetings and what each vote means](https://pepvault.app/guides/fda-peptide-panel-explained)
- [Low-dose naltrexone (LDN): what it's used for and what the trials show](https://pepvault.app/guides/low-dose-naltrexone)
- [Is low-dose naltrexone (LDN) safe in pregnancy, and before trying to conceive?](https://pepvault.app/guides/ldn-and-pregnancy)
- [Do you stop low-dose naltrexone (LDN) before surgery or a colonoscopy?](https://pepvault.app/guides/ldn-before-surgery)
- [Does minoxidil cause hair loss?](https://pepvault.app/guides/minoxidil-shedding)
- [Can you take minoxidil with finasteride?](https://pepvault.app/guides/minoxidil-with-finasteride)
- [Peptides for hair growth: what the studies show](https://pepvault.app/guides/peptides-for-hair-growth)
- [Peptides for skin: what the human studies show](https://pepvault.app/guides/peptides-for-skin)
- [Do tanning peptides protect you from the sun?](https://pepvault.app/guides/tanning-peptides-and-the-sun)
- [Tretinoin vs retinol vs GHK-Cu for skin](https://pepvault.app/guides/tretinoin-vs-retinol-vs-ghk-cu)
- [Epitalon and telomeres: what was measured](https://pepvault.app/guides/epitalon-and-telomeres)
- [Dihexa: what is known, and what is not](https://pepvault.app/guides/dihexa-what-is-known)
- [Does Pinealon help sleep, and why does it make some people sleepy?](https://pepvault.app/guides/pinealon-and-sleep)
- [Selank vs oxytocin for anxiety: what the trials found](https://pepvault.app/guides/selank-vs-oxytocin-for-anxiety)
- [Oxytocin nasal spray: what it is used for](https://pepvault.app/guides/oxytocin-nasal-spray)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Cycle](https://pepvault.app/glossary/cycle)
- [Stack](https://pepvault.app/glossary/stack)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Accelerated approval](https://pepvault.app/glossary/accelerated-approval)
- [Open-label](https://pepvault.app/glossary/open-label)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
